SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results for the second quarter ended June 30, 2006. For the second quarter 2006, revenues from the sale of ZADAXIN®, SciClone’s lead product, increased by 15% to $7,910,000, compared with ZADAXIN revenues of $6,851,000 for the second quarter 2005. For the six months ended June 30, 2006, revenues totaled $15,699,000, an increase of 16% compared with revenues of $13,512,000 for the same period of 2005. This increase in product revenues for the second quarter and first half 2006 is primarily attributable to an increase in the quantity of ZADAXIN sold to the Chinese market, which accounts for over 90% of overall ZADAXIN sales. Contract revenue for the second quarter 2006 was $54,000 compared with $134,000 for the second quarter 2005. For the six months ended June 30, 2006, contract revenue was $144,000 compared with $268,000 for the same period of 2005.
